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AbstrACt
Objectives To explore older people’s perspectives and 
experiences with shared decision-making (SDM) about 
medication for cardiovascular disease (CVD) prevention.
Design, setting and participants Semi-structured 
interviews with 30 general practice patients aged 75 years 
and older in New South Wales, Australia, who had elevated 
CVD risk factors (blood pressure, cholesterol) or had 
received CVD-related lifestyle advice. Data were analysed 
by multiple researchers using Framework analysis.
results Twenty eight participants out of 30 were on CVD 
prevention medication, half with established CVD. We 
outlined patient experiences using the four steps of the 
SDM process, identifying key barriers and challenges: Step 
1. Choice awareness: taking medication for CVD prevention 
was generally not recognised as a decision requiring patient 
input; Step 2. Discuss benefits/harms options: CVD prevention 
poorly understood with emphasis on benefits; Step 3. Explore 
preferences: goals, values and preferences (eg, length of life 
vs quality of life, reducing disease burden vs risk reduction) 
varied widely but generally not discussed with the general 
practitioner; Step 4. Making the decision: overall preference 
for directive approach, but some patients wanted more 
active involvement. Themes were similar across primary and 
secondary CVD prevention, different levels of self-reported 
health and people on and off medication.
Conclusions Results demonstrate how older participants 
vary widely in their health goals and preferences for 
treatment outcomes, suggesting that CVD prevention 
decisions are preference sensitive. Combined with the 
fact that the vast majority of participants were taking 
medications, and few understood the aims and potential 
benefits and harms of CVD prevention, it seems that older 
patients are not always making an informed decision. Our 
findings highlight potentially modifiable barriers to greater 
participation of older people in SDM about CVD prevention 
medication and prevention in general.
IntrODuCtIOn  
One of the biggest challenges of our time 
is optimising health and quality of life for 
our rapidly growing ageing population. Up 
to 70% of older people have two or more 
chronic conditions which complicates 
decision-making.1 2 Treatments that improve 
one condition might make another worse, may 
have long-term benefits but short-term harms, 
and multiple medications (and their interac-
tions) must be balanced.3 In addition, taking 
multiple medicines, frequent healthcare visits, 
refilling prescriptions, making lifestyle changes 
and self-managing care can be a significant 
burden on patients and their family/carers.4 
A patient-centred approach to healthcare deci-
sion-making can help to ensure that the bene-
fits outweigh the harms, they serve the larger 
aims of the older person’s life and impose 
the smallest possible burden. Shared deci-
sion-making (SDM) can help achieve this.
SDM aims for clinicians and patients to 
collaboratively make a health decision after 
discussing the options and benefits and 
harms, and considering the patient’s values, 
goals, preferences and circumstances.5–7 
The case for SDM among older adults, espe-
cially those with multimorbidity, is particu-
larly strong6; decisions in this context can 
be considered highly preference sensitive, 
evidence around potential benefits and 
harms of treatments for older people is often 
limited, and involves the weighing of many 
factors (eg, patient capacity, social support, 
carers, burden of treatment). The best 
option therefore strongly depends on which 
strengths and limitations of this study
 ► This study draws from a diverse sample of older 
people living in New South Wales, Australia.
 ► Data was rigorously analysed by multiple research-
ers using Framework analysis.
 ► The majority of participants were on preventive car-
diovascular disease medication, which means that 
while representative of the population, our findings 
are limited in terms of people who choose not to 
take medication.
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outcomes matter the most to the individual older patient 
and what option best fits their circumstances.6 Further, 
older people's preferences will vary widely depending on 
factors such as their frailty, level of education, cognitive 
and health status and tolerance of side effects, providing 
another argument for a tailored and shared approach to 
decisions.3 However, the same factors that increase the 
importance of SDM in older people also make it more 
complicated, not to mention the additional challenges 
of age-related cognitive changes and communication 
barriers such as hearing loss.8 9
Medication for the primary and secondary preven-
tion of cardiovascular disease (CVD), including statins 
and antihypertensives, are among the most commonly 
prescribed medications in people aged 75 years and 
older.10 At the same time, the evidence around potential 
benefits and harms of these medication for older people 
is limited11 12 because they are poorly represented in clin-
ical trials and most CVD guidelines are based on cohorts 
with an age cut-off.13 14 For example, many CVD risk 
prediction models are not well validated in older people. 
The widely used Framingham risk equation that is used 
in the Australian primary CVD prevention guidelines,15 
for instance, is based on a patient cohort with an upper 
age of 74.16 For a large proportion of older people, the 
decision to start CVD medication was made at a younger 
age and could therefore be informed by evidence-based 
guidelines, however once people reach the age cut-off for 
trials, they enter the ‘non-evidence-based zone’.17 Even where 
evidence suggests benefits of preventive medication for 
older people, as is the case for secondary prevention, the 
evidence becomes uncertain in the context of complex 
interactions between multiple conditions and medica-
tions, the generally higher risk of side effects, declining 
health and limited life expectancy as trial data is not avail-
able for these groups.18 19 It is therefore not a surprise 
that general practitioners (GPs) are uncertain about 
CVD prevention in older age, and there is evidence of 
overtreatment and undertreatment of CVD risk in this 
group.20–22 This is why an SDM approach to CVD manage-
ment has now been universally advocated, in particular 
for those who are older, frail or have comorbidities.23–26
The literature has started to address some of these 
challenges, and changes have been proposed to adapt 
existing SDM models for older patients.6 7 However, 
studies describing the experience of older patients with 
health decisions are still scarce. In this paper, we explore 
older people’s perspectives and experiences with deci-
sions about medication for CVD prevention and describe 
the implications of our findings for SDM in the context of 
preventive medicine in older people.
MethODs
Design
A qualitative study using semi-structured interviews with 
30 general practice patients aged 75 years and above in 
New South Wales, Australia in 2012.
recruitment and participants
Patients were recruited through their GPs from multiple 
clinics throughout Sydney and regional New South Wales; 
the GPs participated in a separate interview study.22 
Participating GPs (n=16) invited up to four patients aged 
75 years and above who had elevated CVD risk factors at 
the time of recruitment (eg, blood pressure, cholesterol) 
or had recently received CVD-related lifestyle advice; the 
latter criterion was aimed at targeting lower risk patients. 
The age cut-off was determined based on the evidence 
gap for this group in the Australian CVD guidelines.15 In 
line with the qualitative approach, we aimed to recruit 
a diverse, purposive sample rather than a representa-
tive sample27 by selecting patients with varying CVD risk 
factors (eg, gender, blood pressure), CVD history, medi-
cation use and experience of CVD events. Thirty eight 
patients returned expression of interest forms, and 30 
participated in the interviews. Recruitment was stopped 
when initial data analysis indicated that meaning satura-
tion had been reached (ie, no new concepts were being 
identified in the data).28 
Patient and public involvement
Patients were not involved in the development of research 
questions, the design, the recruitment to or the conduct 
of this study.
Data collection
Semi-structured interview schedules were developed by the 
research team, piloted with a convenient sample of two 
older persons and revised (see supplementary file). One 
author, trained in public health qualitative methods (SM), 
conducted interviews between February and August 2012. 
Participants signed a consent form before being interviewed 
over the phone (n=25) or in person (n=5), according to 
their preference. Interviews lasted from 8 to 55 min. The 
interviews were audio-recorded and transcribed verbatim. 
The guidelines for CVD prevention15 in Australia have not 
changed substantially since this data was collected.
Data analysis
A Framework analysis method was used to analyse the inter-
view transcripts, which involved 5 steps29 (table 1). Rigour 
was addressed by repeated coding of transcripts by different 
team members to ensure a comprehensive theme list and 
framework was achieved, an iterative process of constant 
comparison between the existing framework and new 
data, detailed documentation of the analysis process and 
discussion of emerging and final themes with all authors.30 
As SDM was a key interest in our data analysis, we used an 
existing SDM framework6 to categorise our data according 
to the different steps of SDM.
results
Demographic and health characteristics of partici-
pants are presented in table 2. Twenty eight partici-
pants out of 30 were on CVD prevention medication, 
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14 of whom had established CVD (quotes marked est. 
CVD). As a result, there was comparatively less data 
about the experiences of people who were not taking 
CVD medication. Participants defined their health 
in terms of presence or lack of serious illness and 
disability, level of independence, whether medical 
conditions were controlled or uncontrolled and rela-
tive to one’s own previous health as well as relative to 
others of a similar age. We report on older patient’s 
experiences with decision-making about medication 
for CVD prevention using the different steps of the 
SDM process.6 Participants’ experiences were very 
similar across primary and secondary CVD prevention.
step 1: Creating awareness that a decision needs to be made 
and options exist
Overall, participants did not recognise taking medication 
for CVD prevention as involving a decision. Medication 
was generally perceived as ‘needed’ without a sense that 
there may be different options to consider. This attitude 
appeared heightened in participants who had expe-
rienced a CVD event or had a family history. Lifestyle 
approaches were perceived as an optional addition rather 
than an alternative to medication.
It’s good for your, your health (…) well fair enough 
you do it. You don’t even ask any questions. (ID72 
est. CVD)
The majority of participants in our study had been on 
CVD medications for at least 5 years with the expecta-
tion of taking them for the rest of their lives. Participants 
described how taking CVD medication is not ‘a big deal’ 
(ID28) and a part of their routine to stay healthy as they get 
older so they ‘don’t think about it anymore’ (ID19, est. CVD). 
One exception was when people experienced side effects. 
This triggered the consideration of alternative options 
including stopping, reducing or changing medication or 
trying lifestyle changes. Side effects and concerns were 
often not discussed with the GP, and some participants 
specifically mentioned barriers around raising the option 
of stopping medication. For example, a patient who 
was keen to try non-medication approaches to lower his 
cholesterol felt discouraged by his GP’s attitude:
You can, can do away with all these medications to 
do with cholesterol (…) But you talk to your doctor, 
they said, they don’t, they don’t seem to believe in it. 
(ID 89)
step 2: Discussing the different treatment options and their 
potential benefits and harms
Several participants demonstrated limited under-
standing of the aim of CVD medication (ie, reducing 
the risk of a future CVD event), assuming that elevated 
blood pressure or cholesterol are diseases needing 
treatment rather than risk factors. Many did not make 
the connection between taking antihypertensives/
statins and CVD and reported that their GP had not 
discussed heart disease or stroke with them, while at the 
same time mentioning discussions they had about their 
blood pressure and cholesterol:
When he takes my blood pressure, I always ask him 
what it is and write it down so that I’ve got a record 
but no we don’t generally discuss heart things. (ID85)
Understanding was not necessarily great in people who 
had experienced a CVD event. For example, one partic-
ipant with an extensive history of CVD (2x stroke, hole 
in the heart, type 2 diabetes) displayed limited under-
standing of his increased CVD risk:
I’m never worried about me heart at all. It’s not too 
bad as far as I, I’m aware. (ID90 est. CVD)
Others expressed a better understanding, mentioning 
for example, how family history, stress, age and diabetes 
increase risk or referring to antihypertensives/statins 
as ‘heart tablets’ (ID75). However, this was by no means 
comprehensive.
Table 1 Data analysis using the 5  key steps of the Framework approach for qualitative analysis 
Framework analysis steps29 Approach
Familiarisation Three authors with a background in public health and psychology (SM, JJ, CB) 
independently read through 5 transcripts and discussed the emerging themes which, 
combined with the interview questions, resulted in a preliminary coding scheme
Creation of a thematic framework SM, JJ and CB read a sample of another 7 transcripts to develop the initial framework 
scheme that was discussed with experienced qualitative researcher KM.
Indexing SM coded the remaining transcripts according to the framework. Twelve of these 
transcripts were also coded independently by JJ to ensure that the framework was 
comprehensive and influenced by varied researcher perspectives. New themes and 
revisions to the framework were discussed with JJ, CB and KM.
Charting SM summarised the themes and supporting quotes from each transcript in the 
framework (a matrix with participants as rows and themes as columns). Transcripts were 
re-read and discussed to resolve any disagreement about the best way to represent the 
data.
Mapping and interpretation SM examined the framework within and across themes and participants to identify 
overarching themes and relationships and discussed her interpretations with JJ and CB.
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My doctor knows I’m diabetic, he has been watching 
me. But obviously that must have something to do 
with the heart. (ID48 est CVD)
step 3: exploring patient preferences for the different 
treatment options
Values, goals and preferences around CVD prevention 
varied widely across participants and included improving 
quality of life or length of life, preventing illness or 
disability, reducing treatment burden, reducing worry 
about CVD or anxiety about taking multiple medications 
and maintaining a strong self-identity. See table 3 for a 
detailed overview and illustrative quotes. Even though 
the vast majority of participants could articulate what was 
important to them, only a few mentioned discussing their 
goals and preferences with their GP, and mostly in the 
context of side effects of CVD medication. The general 
attitude was that age is not a reason to not start, stop or 
change medication. However, some mentioned the finan-
cial and opportunity costs involved in looking after an 
ageing society. Others commented that CVD prevention 
should be ‘appropriately suitable for the age’ (ID44 est. CVD) 
or acknowledged the importance of considering the older 
person’s ‘attitude and their own state of health’ (ID9) when 
making decisions.
step 4: Making the decision and involving the patient to the 
extent they wish
Participants often equated being informed with 
being involved in decisions about CVD medication, 
and patient-centred communication (eg, listening to 
concerns, being caring, thorough, being non-ageist) 
seemed to be valued more than active involvement. Many 
just wanted to know the reason why CVD medication was 
recommended, or changes to medication were suggested. 
They were happy to then follow their GP’s recommen-
dations, generally preferring a directive approach. The 
involvement of others (family, carers) in medication deci-
sions was mentioned by several people.
Oh yes, I’d like to be completely involved, yes. 
INTERVIEWER: When you say completely involved 
you mean (…) PARTICIPANT: Getting as much in-
formation as what I can get. (ID40)
The majority of participants described how they wanted 
‘as much information as possible’ about their CVD medica-
tion; however there were exceptions:
There are people who know, seem to know more 
about the pharmaceutical industry than the pharma-
cist. I’m not in that category, I do as I’m told. (ID31 
est. CVD)
Only three participants described being actively 
involved in the decision-making process; for two this was 
triggered by severe side effects of their CVD medication.
My muscles ached and I didn’t do well on them (a 
lipid lowering medication) and I hated taking them 
so… we’ve come to make a pact, as my HDLs and 
LDLs are a reasonable balance, I just go along with 
my high cholesterol which is monitored on a regular 
basis and lived with. (ID3)
Table 2 Participant characteristics
Characteristic Category n
Sex Male 16
Female 14
Age (years) 75–79 20
80–84 4
85–89 5
90+ 1
Highest education Year 10 or below 17
Year 12 5
Technical diploma 4
Undergraduate university 
degree
1
Postgraduate university 
degree
3
Marital status Never married 1
Married 20
Divorced 3
Widowed 6
Country/region of 
birth
Australia 24
UK 5
Canada 1
Cardiovascular 
disease (CVD) 
medication use
Medication not 
recommended
1
Not taking recommended 
medication
1
Taking preventive 
medication
14
Taking medication after 
CVD event
14
Years taking 
preventive CVD 
medication
Not on any CVD 
medication
2
Less than 5 4
5–9 5
10–19 10
20–29 3
30+ 4
Unknown 2
Number of reported 
current medical 
conditions
At least one 23
Two or more 14
Self-reported health Poor or fair 4
Good, very good or 
excellent
26
 o
n
 1 July 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-026342 on 20 March 2019. Downloaded from 
5Jansen J, et al. BMJ Open 2019;9:e026342. doi:10.1136/bmjopen-2018-026342
Open access
[The GP] made sure that I understood what was 
going to happen (…), and she left the choice [to 
take medication for elevated blood pressure] to me. 
(ID75)
A directive decision-making preference was also related 
to high levels of trust in the GP. Many participants 
expressed long-standing, positive and trusting relation-
ships with their GP, assuming they ‘should know what’s 
best for me’ (ID89). For some participants, trust was mainly 
based on the expertise of medical professionals in general: 
‘she has far more knowledge than I have’ (ID19 est. CVD). 
According to these participants doctors make the deci-
sions and patients should follow their recommendations:
That’s what they’re there for, that’s their job. My job 
is to, to do what they tell me. (ID90 est. CVD)
For others, trust was also about the personal relation-
ship they have with their GP and their shared history, 
Table 3 Goals, values and preferences related to  cardiovascular disease  (CVD) prevention
Goals, values and preferences Illustrative quotes
Length of life versus quality of life
Participants varied in how they valued quality of life versus 
length of life. Some focused-on longevity for example, 
because they wanted to see their grandchildren grow up or 
fulfil other future goals. Other participants prioritised quality 
of life and stressed the importance of providing care for older 
people that does not ‘grasp with (sic) straws’ (ID44 est. CVD). 
According to one participant, cardiologists in particular put too 
much emphasis on prevention when death is inevitable in older 
age. For others, there was an acceptance that the end of life is 
near and unavoidable. Some referenced religious beliefs when 
making such statements.
 ► ‘If there is anything that you can do you do it, if it’s going to 
prolong life.’ (ID22)
 ► ‘My Doctor says I’ll keep you here till you’re 100, I said you 
needn’t bother (laughs).’ (ID44 est. CVD)
 ► ‘Just taking each day as it comes. I’ve sort of…wake in the 
morning and I think that’s a bonus.’ (ID43)
Self-identity
Participants discussed the value of making an active 
contribution to their health through taking CVD medication, 
resulting in a more positive ‘outlook in life’ (ID83) and 
contributing to a feeling of self-worth. In contrast, several 
participants also talked about the sense of personal pride 
provided by not taking any medication.
 ► ‘I’ve never taken any medication or anything in my whole 
life apart from when I, I did have prostate cancer (…) I’ve 
never taken tablets up until I took this blood pressure tablet. 
I didn’t like that idea.’ (ID61)
Reducing anxiety and worry
Some participants who seemed to have a good understanding 
about CVD risk talked about how taking medication made 
them less worried about having a heart attack or stroke and/or 
becoming ‘a burden to yourself or others’ (ID31 est. CVD). At 
the same time, taking multiple medications caused anxiety for 
others.
 ► ‘I felt quite relieved because I thought at the stage that I was 
in I was worried I might have had a serious setback in terms 
of a stroke or heart attack or whatever.’ (ID92)
 ►  ‘I take so many different tablets it’s frightening. For each 
different thing that I have wrong with me.’ (ID22)
Preventing illness or disability.
Some participants perceived that you cannot stop yourself 
from getting older, but by taking medication you have some 
control over your health and future.
Others talked more generally about how prevention is better 
than cure. Many referred to having the responsibility to do 
‘what you have to do’ (ID58 est. CVD) to look after your health 
and how taking CVD prevention is an inherent part of this 
as you get older. Some participants had the more fatalistic 
view that heart disease is just ‘par for the course’ (ID22) of 
getting older, however this did not dissuade them from taking 
medication.
 ► ‘I think it’s advisable to keep control, keep your eye on these 
various factors so that you…extend your life and make it 
more healthy.’ (ID28)
 ► ‘Whether it be the human body or a piece of machinery 
there is certain… shall we say preventative maintenance 
programmes to help.’ (ID31 est. CVD)
 ► ‘I think if you’re over 80, you, you, you’re thinking a lot more 
about young people, by accident or by bad fortune and 
that are handicap particularly, that they should have some 
priority.’ (ID 75)
Reduce treatment burden
Participants discussed potential harms of antihypertensives 
(eg, feeling faint and weak, low energy, headaches) and statins 
(muscle aches). A few described how they had experienced 
side effects that were so severe that they decided to stop their 
medication together with their general practitioner  (see Step 
4). Some participants described the burden of taking multiple 
medications and the confusion it could cause. However, most 
participants accepted the benefits of medication as being 
worth the nuisance.
 ►  ‘It was getting a bit much, (…) before I had the Webster 
pack, if, it was getting a bit much.’ (ID43)
 ► ‘I’m having plenty of treatment at the moment so and I think 
that’s going to be an ongoing thing and I think when you’ve 
got something wrong with you well you, you should do the 
best you can to treat it to be as well as you can.’ (ID 88 est. 
CVD)
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with an implicit assumption that GPs are not only medical 
experts but also know and understand what matters to 
their older patients.
He refers to me, like, he’ll tell me, his mother’s the 
same age as me and he, he tells me what he tells his 
mother. It’s a very intimate consultation. (ID82, est 
CVD)
Used to say he [previous GP for 35 years] was more of 
a friend than a Doctor because I had been with him 
for so long. (ID43)
DIsCussIOn
This qualitative investigation into older people's (75+) 
experience of decision-making in the context of CVD 
prevention medication revealed that although the 
majority of participants were taking medications, only a 
few seemed to fully understand their purpose and poten-
tial benefits and harms. Participants varied widely in 
their goals and preferences related to CVD, and defined 
involvement in decision-making less in terms of making 
the final decision, and more in terms of being informed. 
There was surprising commonality in the experiences 
of these patients and across primary and secondary 
prevention.
In our study, most people had been taking CVD medi-
cation for a very long time, had faith in the importance 
of prevention, and were taking medication because it was 
the apparent default decision.6 31 Cognitive biases such 
as status quo bias, cognitive dissonance and confirma-
tion bias may provide an explanation.6 However, several 
of our findings suggest that older patients are not always 
in a position to make an informed health decision. Most 
participants conveyed limited knowledge about the aims 
and potential benefits and harms of CVD medication 
and often held the assumption that CVD prevention is 
effective regardless of age. They demonstrated limited 
choice awareness regarding alternatives (not starting, 
stopping, reducing or changing medication or trying life-
style change) unless they were experiencing side effects 
or had a strong negative attitude towards medication. 
Other studies have similarly found what is often referred 
to as ‘low choice awareness’ or ‘low decision awareness’ 
in older people.32 A systematic review of studies using 
the Observing Patient Involvement in Decision Making 
(OPTION) Scale to assess SDM found that only in 1 in 
3 studies clinicians made it clear that there was more than 
one option to consider.33 This is problematic given that 
older people may have different preferences for CVD 
prevention when fully informed. Fried et al, for example, 
have shown in an experimental study with hypothetical 
scenarios that older people are less willing to take medica-
tion for primary prevention of CVD when provided with 
information about potential harms in addition to benefits 
compared with benefit information only.34
Our results also suggest that decisions may not always 
be concordant with goals, values and preferences. The 
health goals and priorities of participants in our study 
varied widely. This occurred across different categories 
of goals, including fundamental goals (eg, living as long as 
possible vs as healthily as possible); functional goals (eg, 
staying active vs being free of worry) and disease/symptom 
specific goals (ie, avoiding symptoms or side effects, 
reducing risk of stroke).35 A quantitative study revealed 
similarly variable health goals and preferences in older 
patients; half of the older participants identified reducing 
the risk of cardiovascular events as more important than 
reducing their combined risk of fall injuries or medica-
tion symptoms, whereas the other half of the participants 
identified the opposite priorities.36 Few participants in 
our study mentioned discussing their goals with their 
GP and demonstrated trust in the GP’s understanding 
of their preferences and circumstances. This is in line 
with other qualitative studies which have found that 
older patients may not start conversations because they 
assume the clinician knows what matters to them.32 Clini-
cians, similarly, do not initiate these discussions and may 
assume they know the patient's preferences.32 However, 
unless actively discussed, there is likely to be a mismatch 
between the clinician's perception of patient preferences 
and the patient’s actual preferences.37 38 Patients may also 
think that their preferences or concerns are irrelevant to 
the decision- making process because the clinician does 
not enquire about it. Combined, these findings suggest 
that these decisions are highly preference sensitive and 
that preferences and goals cannot be assumed and need 
to be explicitly discussed.
Directions for research and practice
In our study and others, older people valued a caring, 
person-centred approach to healthcare where they felt 
heard and understood by their GP.39–41 Older people also 
defined involvement less in terms of making the final 
decision and more in terms of being informed.42 43 This 
aligns with a general finding that most (but not all) older 
people prefer a more passive role in decision- making.44 45 
These results seem to be partly due to a cohort effect,46 
and together with the ageing of the baby boomer gener-
ation, suggest that there is a growing space for using a 
SDM approach with older people. In addition, both 
in our study and in previous work, older people were 
heterogeneous regarding their desired involvement 
in decision-making40 41 43 which emphasises that older 
patients’ preferences should not be assumed. Rather, 
patients should be encouraged and supported by GPs to 
be involved, but ultimately it is up to the patient to decide 
how much they want to participate. Even if the final deci-
sion is made by the GP, if patients are actively engaged in 
the information exchange and discussion of preferences, 
it should still be considered a shared decision.
Strategies to address barriers and challenges of SDM 
about CVD medication are presented in table 4. Decision 
aids for CVD prevention are available47 and might be a 
good starting point for information-exchange. However, 
in order to be effective, decision aids should be developed 
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with older people and comorbidities in mind.48 Clini-
cians also need an understanding of how to adapt the 
evidence for older people.22 Additional guidance on how 
long CVD medication should be prescribed and circum-
stances in which it can be reduced or stopped, both in 
clinical guidelines13 and patient education materials, is 
also needed to support these conversations. In addition 
to decision aids, question prompt lists have been devel-
oped and have successfully empowered patients to discuss 
the potential benefits and harms of different options49; 
our results suggest that similar interventions may be 
needed to encourage patients to share what matters to 
them with their health provider. These tools will need 
to be supported by specific discussions around prefer-
ences during consultations, a necessary step, given that 
preferences and values described by participants in our 
study (eg, avoiding being a burden) differ from what is 
typically reported in clinical guidelines for primary CVD 
prevention23 and broader health goals and preferences 
for universal health outcomes (eg, staying alive longer) 
only modestly predict people’s preferences for CVD 
medication.50
strengths and limitations
This is a selective patient sample with only two people 
not on preventive CVD medication. Although this limits 
interpretation of the findings, it is representative of this 
population.10 A clear strength of this study is the diverse 
sample of older patients who vary in terms of primary 
and secondary prevention, how long they had been 
taking CVD medication but also their age, education 
and comorbidities. There was a time gap between data 
collection (2012) and publication (2019); however a 
recent systematic review suggests that the same barriers 
to SDM in CVD care in general practice still apply, with 
limited support and guidance available for GPs.51 As this 
is a qualitative study, the generalisability of these findings 
may be limited. We have taken steps to enhance transfer-
ability by describing the research context and methods52 
and relating our results to existing models and evidence 
Table 4 Strategies for general practitioners (GPs) to address the barriers and challenges of shared decision-making (SDM) 
about cardiovascular disease (CVD) medication as identified in this study
SDM step6 Key barriers/challenges How to address barrier/challenges
Example of useful 
strategies for GPs
Creating awareness 
that options exist 
and a decision can 
be made
Limited awareness that:
There are options to consider (unless 
prevented by side effects).
Patient can share information about 
goals, preferences and context.
Acknowledge that past decisions may 
need to be revised.
Make goals explicit, explain that 
health provider is the medical expert 
and that the patient is the expert on 
his/her life, goals and circumstances.
Consider SDM as an 
ongoing process7
Collaborative goal setting 
as the key first SDM 
step35 55
Preparation for SDM56
Discussing the 
options and their 
potential benefits 
and harms
Limited knowledge of:
Aims of CVD medication.
Potential benefits and harms.
How age-related concerns may 
impact benefit/harm trade off 
in medication.
Limitations of evidence on older 
people.
Ensure patients are knowledgeable 
enough to construct informed 
preferences.
Discuss potential harms as well as 
benefits.
Discuss why it is important to take 
age-related concerns into account 
in decision-making about CVD 
medication.
Acknowledge limitations and 
uncertainties of the evidence.
Empower patients to ask 
questions about CVD 
prevention options (eg, 
ASK 3)57 58
Use a teach back 
approach to check 
understanding59
Use decision aids for CVD 
prevention47
Exploring 
preferences 
for (attributes of) 
different options
Preferences vary widely (both health-
related and with regard to decision 
involvement).*
Assumption that preferences are 
known to GP.
Cognitive biases (eg, status quo 
bias, confirmation bias, cognitive 
dissonance) leading to preferences 
for medication and focus on benefits 
over harms.
Explicitly invite patients to express 
preferences and link them to different 
options and potential benefits and 
harms.
Challenge preferences that appear 
misinformed.
Use patient-centred 
communication60
Use decision aids for CVD 
prevention47
Use tool to prioritise 
outcomes37
Making the decision Preference for directive approach, but 
some want more active involvement.
Perception that being informed=being 
involved.
Carer involvement.
Encourage and support patients to be 
involved, accept that some may not 
want to be.
Explore involvement of family 
members/carers.
Use a triadic  SDM 
approach61
*see table 3 for detailed overview of goals, values and preferences.
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from the literature. A follow-up quantitative survey could 
be carried out to confirm our findings are generalisable 
to the older population at large.
Most participants in our study had been taking CVD 
medication for over a decade, around half of them for 
established CVD. In other words, this is not the typical 
SDM context of new decisions about new medication. 
However, it is a common scenario for older people, in 
particular those with multimorbidity. Rather than being a 
limitation of the study, this speaks of the need to reframe 
SDM in this context to include a periodic re-evaluation 
of decisions that have been made in the past. This would 
include ongoing conversations about medication to 
ensure treatments are still of benefit and remain feasible 
and might include discussions around reducing or stop-
ping CVD medication.7 19 This approach may also improve 
adherence to essential CVD medication.53 54 Especially in 
the absence of triggers such as acute side effects, it may 
be challenging and counterintuitive for older patients to 
initiate these discussions6 and health providers might be 
reluctant to ask because they perceive they lack time or 
skills.22
COnClusIOns
Our aim in this study was to explore older people’s 
perspectives and experiences with decisions about medi-
cation for CVD prevention. Our results suggest that 
decision-making for many older patients might be more 
about re-evaluating and adjusting medication decisions 
made in the past than about new medication. To ensure 
that decisions are informed and aligned with patient 
preferences and goals, GPs may need to spend extra time 
regularly reviewing medications, explaining the aims of 
prevention, explaining that there are different options 
to consider and importantly, eliciting personal goals 
and preferences. Clearly this can be a time-consuming 
process. Protected time, more dedicated resources, and 
even specific remuneration for discussions around goals 
and preferences and monitoring and reviewing medica-
tion may be needed.
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